Sellas Life Sciences stock faces downside risk ahead of REGAL Phase 3 data, and the valuation looks stretched. Click here to ...

Scripps Research scientists have developed a new class of drug compounds that reduce harmful inflammation while leaving the body's ability to fight infections intact—a long-sought goal in treating ...

A new study sheds light on why some patients with the most aggressive form of ovarian cancer respond better to treatment than others. Tumors positive for a molecule called MHC class II are linked to ...

We all struggle with self-control sometimes. We tell ourselves only one more piece of chocolate, one more glass of wine, one more episode of a binge-worthy series before bed, but then carry on ...

DeepSeek researchers have developed a technology called Manifold-Constrained Hyper-Connections, or mHC, that can improve the performance of artificial intelligence models. The Chinese AI lab debuted ...

Please provide your email address to receive an email when new articles are posted on . Restoret activates Wnt in the retinal vasculature. Tiespectus is a Tie2 agonist that blocks VEGF. ORLANDO — Two ...

SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and ...

Efficacy and safety of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: A prospective, single-arm, phase II trial. Serplulimab versus ...

A new class of molecules capable of killing the cancer cells that are refractory to standard treatments and responsible for recurrence has just been developed. This crucial advance in the fight ...

Current anticancer treatments essentially target the primary tumor cells that proliferate quickly, but do not effectively eliminate specific cancer cells able to adapt to existing treatments and which ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...

Add Popular Science (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.